New Study Looks at HuMOLYTE® and Chemotherapy-Related Mucositis
Cancer treatment is hard enough without painful mouth sores, diarrhea, dehydration, and trouble eating.
For many patients, these side effects are not “minor.” They can affect nutrition, energy, comfort, and even whether treatment stays on schedule.
A new peer-reviewed study published in Frontiers in Nutrition looked at a medical food called HuMOLYTE® and its possible role in reducing chemotherapy-induced mucositis in Wistar rats. Mucositis means inflammation and injury to the moist lining of the mouth and digestive tract. It can happen when chemotherapy damages fast-growing healthy cells along with cancer cells.
This study is early-stage and preclinical, meaning it was done in animals and lab-grown cells, not yet in cancer patients. Still, it gives caregivers, patients, and clinicians a clearer look at how gut support may matter during chemotherapy.
What Was This Study About?
The study tested whether HuMOLYTE®, a medical food containing 2′-fucosyllactose, also called 2′-FL, plus electrolytes including magnesium, sodium, and potassium, could help protect the gut and mouth from chemotherapy damage.
2′-FL is a type of human milk oligosaccharide, or HMO. HMOs are special carbohydrates first found in human milk. They are not digested like regular sugar. Instead, they help support gut barrier function and healthy gut bacteria.
The researchers tested HuMOLYTE® against four chemotherapy drugs known to cause gut or mouth injury:
Doxorubicin
Irinotecan
5-fluorouracil, often called 5-FU
Cisplatin
These are commonly used chemotherapy drugs in different cancer treatment plans. The goal was not to test whether HuMOLYTE® treats cancer. It does not. The goal was to study whether it may help reduce some of the gut and mouth side effects caused by chemotherapy.
Why Mucositis Matters During Chemotherapy
Mucositis can affect the body from the mouth to the intestines.
In the mouth, it may cause:
Painful sores
Trouble swallowing
Poor appetite
Trouble drinking enough fluids
In the gut, it may cause:
Diarrhea
Cramping
Inflammation
Poor nutrient absorption
Dehydration
Electrolyte loss
This matters because dehydration and electrolyte problems can make patients feel weaker. In some cases, patients may need IV fluids, treatment delays, or dose changes.
Magnesium is especially important. The study notes that chemotherapy-related diarrhea and dehydration can lead to electrolyte loss, including magnesium and potassium. Magnesium can be difficult to replace because some forms of magnesium may worsen diarrhea. That creates a tough cycle: the gut is injured, magnesium is lost, and replacing magnesium orally may be hard for some patients.
How the Study Was Designed
The researchers used Wistar rats and divided them into groups. Some received regular water. Others received HuMOLYTE® mixed in drinking water.
The HuMOLYTE® group started supplementation five days before chemotherapy and continued after chemotherapy. Then the rats received one of the chemotherapy drugs.
Researchers measured several outcomes:
Diarrhea severity
They scored bowel movements from normal stool to severe watery diarrhea.Weight loss
Weight loss can be a sign of dehydration, poor food intake, and gut injury.Gut tissue damage
The researchers looked at ileal and colonic tissue under a microscope.Oral tissue damage
They studied mouth tissue for signs of inflammation, swelling, and injury.Cell studies in the lab
They tested whether HuMOLYTE® affected gut cell survival, barrier strength, and mucin production.
Mucin is the slippery protective substance made by goblet cells. Think of mucin like the body’s natural “protective coating” for the gut lining.
Key Finding #1: HuMOLYTE® Reduced Diarrhea Severity
The study found that chemotherapy caused diarrhea in most treatment groups, especially with irinotecan and 5-FU.
Rats that received only water had more severe diarrhea. Rats that received HuMOLYTE® had lower diarrhea scores.
This was especially clear in the 5-FU group, where rats receiving HuMOLYTE® had normal bowel movement scores during the study period, while rats receiving 5-FU with water developed diarrhea. The irinotecan group still had diarrhea, but the severity was lower with HuMOLYTE®.
For patients and caregivers, the practical point is simple: diarrhea during chemotherapy is not just uncomfortable. It can drive dehydration, weakness, and electrolyte loss. A product that may reduce diarrhea severity deserves further study in humans.
Key Finding #2: HuMOLYTE® Reduced Weight Loss
Chemotherapy-treated rats lost weight after treatment. This was expected because diarrhea and gut injury can reduce food intake and fluid balance.
The study found that rats receiving HuMOLYTE® generally lost less weight than rats receiving water.
The irinotecan group had the most severe weight loss. Rats receiving irinotecan with water lost an average of about 44.6 grams, while rats receiving irinotecan with HuMOLYTE® lost about 25.2 grams. The doxorubicin and 5-FU groups also showed less weight loss with HuMOLYTE®.
This matters because maintaining weight during chemotherapy is often a major concern. Weight loss can reflect dehydration, poor nutrition, inflammation, or treatment stress.
Key Finding #3: HuMOLYTE® Helped Preserve Gut Tissue
The researchers looked at gut tissue under a microscope. Chemotherapy caused several types of damage, including inflammation, loss of gut structure, loss of goblet cells, and injury to the intestinal lining.
Rats that received HuMOLYTE® had less tissue damage. Their gut lining showed better preserved structure, fewer signs of inflammation, and more goblet cells.
Goblet cells are important because they produce mucin. Mucin helps protect the gut wall. A healthier mucus layer may help the gut stay more resilient during stress.
In plain English: the gut lining looked more protected in the HuMOLYTE® groups than in the water-only groups.
Key Finding #4: HuMOLYTE® Reduced Oral Tissue Injury
Mucositis does not only happen in the intestines. It can also affect the mouth.
The study found that chemotherapy caused oral tissue injury, including swelling, inflammation, and epithelial changes. Epithelial tissue is the thin protective layer that lines surfaces like the mouth and gut.
HuMOLYTE® reduced the severity of oral mucosal injury in the chemotherapy-treated rats. This was seen across the chemotherapy drugs tested, with especially notable findings in the doxorubicin group.
For patients, mouth sores can be one of the most painful and frustrating parts of treatment. They can make it hard to eat, drink, and sleep. This study does not prove HuMOLYTE® prevents mouth sores in humans, but it supports further clinical research.
Key Finding #5: HuMOLYTE® Improved Gut Cell Function in Lab Studies
The researchers also ran lab studies using intestinal cell models.
They found that HuMOLYTE®:
Improved goblet cell survival when cells were exposed to cisplatin.
Improved gut barrier function, meaning the cell layer became less “leaky.”
Increased mucin production, which may help support the gut’s protective lining.
The study compared HuMOLYTE® with Gatorade® in some lab tests. Gatorade® contains electrolytes but does not contain 2′-FL. In these experiments, HuMOLYTE® performed better on cell survival and barrier function.
That suggests the benefit may not come from electrolytes alone. The combination of 2′-FL and electrolytes, especially magnesium, may be important.
What This Means for Cancer Patients and Caregivers
This study is promising, but it is important to be clear.
This was not a human clinical trial. It was a preclinical study in rats and lab-grown cells. Results in animals do not always translate to people.
Still, the study offers a useful direction.
Chemotherapy side effects are often managed after they appear. Patients may receive IV fluids, pain relief, mouth rinses, anti-diarrhea medicines, or nutrition support. Those tools matter. But this study points to a different question:
Can the gut lining be supported before and during chemotherapy to reduce the severity of damage?
That is the bigger idea.
For patients and caregivers, the takeaway is not to self-treat or replace medical advice. The takeaway is to ask better questions:
Am I at risk for chemotherapy-induced mucositis?
What can I do to support hydration during treatment?
Should I monitor electrolytes, including magnesium?
What should I do if diarrhea starts?
Are there medical foods or supportive nutrition options appropriate for my treatment plan?
Always talk with your oncology team before starting any new product during cancer treatment, including medical foods, supplements, or electrolyte products.
Study Limitations
Every good study has limits. This one does too.
It was done in rats, not humans.
Rat digestion, microbiome, diet, and chemotherapy response are not identical to humans.The study used single chemotherapy drugs.
Many cancer patients receive combination chemotherapy. Side effects may be different when drugs are combined.The study was short.
Longer studies are needed to understand effects over multiple chemotherapy cycles.More human data is needed.
The authors state that clinical research is needed to validate these findings in cancer patients.Conflict of interest should be noted.
Some authors were employed by companies connected to the product or research services. That does not invalidate the findings, but it is important context for readers.
Bottom Line
This peer-reviewed study found that HuMOLYTE®, a medical food containing 2′-FL HMO and electrolytes, reduced chemotherapy-related diarrhea, weight loss, oral tissue injury, gut inflammation, and intestinal barrier damage in preclinical models.
The most practical message is this: gut support during chemotherapy deserves more attention. For cancer patients and caregivers, hydration, nutrition, and symptom prevention are not side issues. They are part of getting through treatment with strength, comfort, and dignity.
Talk with your oncology team before using any supportive nutrition product during chemotherapy.
FAQ
What is chemotherapy-induced mucositis?
Chemotherapy-induced mucositis is damage and inflammation in the lining of the mouth or digestive tract caused by chemotherapy. It can lead to mouth sores, pain, diarrhea, poor eating, dehydration, and electrolyte loss.
What is HuMOLYTE®?
HuMOLYTE® is a medical food that contains 2′-fucosyllactose, also called 2′-FL, along with electrolytes such as magnesium, sodium, and potassium. In this study, researchers tested whether it could reduce chemotherapy-related gut and mouth injury in rats.
What is 2′-FL?
2′-FL is a human milk oligosaccharide, or HMO. HMOs are special carbohydrates first found in human milk. They help support gut barrier function and may help feed beneficial gut bacteria.
Did this study prove HuMOLYTE® works in cancer patients?
No. This was a preclinical study using rats and lab-grown cells. It does not prove that HuMOLYTE® works in humans. Human clinical trials are needed.
What chemotherapy drugs were tested?
The study tested doxorubicin, irinotecan, 5-FU, and cisplatin. These drugs are known to cause gut or mouth side effects in some patients.
What were the main results?
HuMOLYTE® reduced diarrhea severity, reduced weight loss, helped preserve gut tissue, lowered oral tissue injury, improved gut barrier function, and increased mucin production in the study models.
Can cancer patients take HuMOLYTE® during chemotherapy?
Patients should talk with their oncology team before using HuMOLYTE® or any supportive nutrition product during chemotherapy. Every treatment plan is different.
Why is magnesium important during chemotherapy?
Magnesium helps support normal cell and body function. Some chemotherapy drugs and diarrhea can contribute to magnesium loss. Low magnesium may worsen weakness, discomfort, and other health problems.
Is this a cancer treatment?
No. HuMOLYTE® is not a cancer treatment and does not replace chemotherapy, radiation, immunotherapy, or any prescribed cancer care. This study looked at supportive nutrition during chemotherapy-related side effects.
What should caregivers watch for during chemotherapy?
Caregivers should watch for diarrhea, mouth sores, poor fluid intake, dizziness, weakness, confusion, reduced urination, rapid weight loss, or signs of dehydration. Report these symptoms to the oncology team quickly.
Reference
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making any changes to your treatment plan, hydration strategies, or diet. The information provided here is based on general insights and may not apply to individual circumstances.
